Change of 0.44% for UCB S A ORDINARY SHARES BELGIUM (OTCMKTS:UCBJF)’s short interest was registered. FINRA announced in February UCBJF’s total 481,500 short interest. The up change of 0.44% from 479,400 shares was reported. UCB S A ORDINARY SHARES BELGIUM (OTCMKTS:UCBJF) has 200 shares average volume. It’ll cost 2408 days for UCBJF to recover its former position.

$88.67 was the last price.It’s since February 10, 2018 and is 0.00% down. UCBJF the S&P500 by 0.00%.

UCB SA, a biopharmaceutical company, focuses on the discovery and development of medicines and solutions for people living with severe diseases of the immune system or of the central nervous system.The firm is worth $16.53 billion. The Company’s core products include Cimzia for ankylosing spondylitis, axial spondyloarthritis, Crohn??s disease, psoriatic arthritis, and rheumatoid arthritis; Keppra, Vimpat, and Briviact for epilepsy; and Neupro for Parkinson??s disease and restless legs syndrome.16.42 is the P/E ratio. The firm also offers Zyrtec and Xyzal for allergy; Venlafaxine ER for depressive and anxiety disorders; Nootropil for cognitive disorders; and Xyrem for narcolepsy.

More recent UCB SA (OTCMKTS:UCBJF) news were brought out by Seekingalpha.com, Seekingalpha.com and Seekingalpha.com. The first one has “UCB’s Cimzia successful in late-stage study in subtype of ankylosing spondylitis – Seeking Alpha” as a title and was brought out on May 16, 2018. The next is “UCB S.A. ADR 2018 Q2 – Results – Earnings Call Slides – Seeking Alpha” on July 26, 2018. And last was brought out on January 08, 2018, called “EMA accepts UCB’s marketing application for osteoporosis med romosozumab – Seeking Alpha”.